Efficacy of intra-articular bevacizumab for relapsing diffuse-type giant cell tumour

Nissén, Michael John; Boucher, Astrid; Brulhart, Laure; Ménétrey, Jacques; Gabay, Cem

doi:10.1136/annrheumdis-2013-204589

Cited by 9 publications

(6 citation statements)

References 10 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinical studies specifically targeting VEGF or angiogenesis in OA, cartilage repair, or RA have not been reported. However, bevacizumab has been used clinically off‐label for IA injection at the knee joint for pigmented villonodular synovitis with high efficacy in a case report, and a clinical trial is underway for IA injection of bevacizumab in recurrent hemarthrosis with chronic hemophilic synovitis (http://clinicaltrials.gov NCT02060305). Hemophilic arthropathy and OA may share similar degenerative pathological pathways of disease progression involving VEGF signaling .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Targeting VEGF and Its Receptors for the Treatment of Osteoarthritis and Associated Pain

Hamilton

Nagao

Levine

et al. 2016

Journal of Bone and Mineral Research

204

188

View full text Add to dashboard Cite

Increased vascular endothelial growth factor (VEGF) levels are associated with OA progression. Indeed, VEGF appears to be involved in OA specific pathologies including cartilage degeneration, osteophyte formation, subchondral bone cysts and sclerosis, synovitis, and pain. Moreover, a wide range of studies suggests that inhibition of VEGF signaling reduces OA progression. This review highlights both the potential significance of VEGF in OA pathology and pain as well as potential benefits of inhibition of VEGF and its receptors as an OA treatment. With the emergence of the clinical use of anti-VEGF therapy outside of OA, both as high dose systemic treatments and low dose local treatments, these particular therapies are now more widely understood. Currently, there is no established disease-modifying drug available for patients with OA, which warrants continued study of the inhibition of VEGF in OA, as standalone or adjuvant therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Throughout the remainder of this text, VEGF-A is referred to as VEGF. Major human isoforms of VEGF, which result from alternative splicing, include VEGF 121 , VEGF 165 , VEGF 189 , and VEGF 206 . (9,10) Murine counterparts of human VEGF include VEGF 120 , VEGF 164 , VEGF 188, and VEGF 205 .…”

Section: Introductionmentioning

confidence: 99%

Targeting VEGF and Its Receptors for the Treatment of Osteoarthritis and Associated Pain

Hamilton

Nagao

Levine

et al. 2016

Journal of Bone and Mineral Research

204

188

View full text Add to dashboard Cite

show abstract

“…Nissen et al investigated the effect of intra-articular injections with bevacizumab as adjuvant therapy after arthroscopic synovectomy in one patient with relapsing D-TGCT located in the knee. 74 During follow-up, complete response was observed, and the patient reported no symptoms nor AEs. Dosage, number of injections and total follow-up duration were not described.…”

Section: Bevacizumabmentioning

confidence: 82%

“…Bevacizumab is a humanized monoclonal VEGF antibody and thus inhibits angiogenesis. Nissen et al investigated the effect of intra‐articular injections with bevacizumab as adjuvant therapy after arthroscopic synovectomy in one patient with relapsing D‐TGCT located in the knee 74 . During follow‐up, complete response was observed, and the patient reported no symptoms nor AEs.…”

Section: Systemic Therapiesmentioning

confidence: 99%

Multimodal management of tenosynovial giant cell tumors (TGCT) in the landscape of new druggable targets

Heijden

Spierenburg

Kendal

et al. 2023

Journal of Surgical Oncology

View full text Add to dashboard Cite

Tenosynovial giant cell tumor (TGCT) is a rare, benign, locally aggressive synovial based neoplastic process that can result in functional debilitation and end‐stage arthrtitis. Although surgical resection is the primary treatment modality, novel systemic therapies are emerging as part of the multimodal armamentarium for patients with unresectable or complex disease burden. This review discusses the pathogenesis of TGCT, potential druggable targets and therapeutic approaches. It also evaluates the safety and efficacy of different systemic therapies.

show abstract

“…Third, systemic therapy is needed to achieve long disease-free situations. For severe or refractory TGCT cases, further adjuvant therapies, including external beam radiotherapy, intra-articular injection of medications, or targeted therapy with pexidartinib are promising (4,38,39). However, by telephone review, we found that the number of patients who received combined therapy after surgery was low.…”

Section: Discussionmentioning

confidence: 99%

Clinical comparison of tenosynovial giant cell tumors, synovial chondromatosis, and synovial sarcoma: analysis and report of 53 cases

Wang¹,

Long²,

Wei³

et al. 2021

Ann Transl Med

View full text Add to dashboard Cite

Background: Tenosynovial giant cell tumors (TGCTs), synovial chondromatosis (SC), and synovial sarcoma (SS) exhibit similarities in clinical features and histochemical characteristics, and differential diagnosis remains challenging in clinical practice.Methods: Data were collected from the pathology database of Shanghai Ninth People's Hospital regarding patients who underwent surgery from 2010 to 2019 with histologically confirmed TGCTs, SC, and SS.Demographic and clinicopathological data of these patients were reviewed. Immunohistochemistry staining of 14 different markers was performed. Correlation analyses of the prognoses were evaluated.Results: A total of 26 patients with TGCTs (8 diffuse TGCTs and 18 localized TGCTs), 16 with SC, and 11 with SS were identified. Pain was the main symptom of patients with both TGCTs and SC, while a palpable mass was the most common symptom for patients with SS. In addition to clinical features, we identified vital risk factors for disease recurrence. The mean follow-up periods were 51, 39, and 14 months for TGCTs, SC, and SS, respectively. Younger patients with diffuse TGCTs or patients with a higher neutrophil/lymphocyte ratio (NLR) displayed a significantly higher frequency of recurrence. We also plotted receiver operating characteristic (ROC) curve analysis for age and NLR. The area under the ROC curve (AUC) was calculated and demonstrated the ability to distinguish recurrent from nonrecurrent cases. In addition, higher CD163 expression was linked to recurrent diffuse TGCT cases. Conclusions: These data indicated possible characteristics of different aspects of TGCTs, SC, and SS.Further clarification and understanding of these factors will help with differential clinical diagnosis and recurrent risk assessment.

show abstract

Efficacy of intra-articular bevacizumab for relapsing diffuse-type giant cell tumour

Cited by 9 publications

References 10 publications

Targeting VEGF and Its Receptors for the Treatment of Osteoarthritis and Associated Pain

Targeting VEGF and Its Receptors for the Treatment of Osteoarthritis and Associated Pain

Multimodal management of tenosynovial giant cell tumors (TGCT) in the landscape of new druggable targets

Clinical comparison of tenosynovial giant cell tumors, synovial chondromatosis, and synovial sarcoma: analysis and report of 53 cases

Contact Info

Product

Resources

About